Revance Therapeutics reported $10.74M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US USD 5.02B 880M
Aerie Pharmaceuticals AERI:US USD 6.93M 3.19M
ALKERMES ALKS:US USD 50.62M 7.74M
Bristol Myers Squibb BMY:US USD 2.35B 324M
Cara Therapeutics CARA:US USD 3.06M 3.06M
Coherus Biosciences CHRS:US USD 35.23M 23.96M
Eli Lilly And LLY:US USD 1.58B 148.6M
Endo International Ordinary Shares ENDP:US USD 176.86M 1.06M
Horizon Pharma HZNP:US USD 234.13M 3.92M
JAZZ PHA JAZZ:US USD 133.66M 9.45M
Johnson & Johnson JNJ:US USD 7.81B 95M
Merk MRK:US USD 3.43B 715M
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Pacira Pharmaceuticals PCRX:US USD 50.68M 51K
Procter & Gamble PG:US USD 10.85B 44M
Revance Therapeutics RVNC:US USD 10.74M 1.21M
Supernus Pharmaceuticals SUPN:US USD 25.88M 5.42M
Teva Pharmaceutical Industries TEVA:US USD 1.88B 73M